Global Markets Direct’s, ‘Secondary Hyperparathyroidism – Pipeline Review, H1 2016’, provides an overview of the Secondary Hyperparathyroidism pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/142048
– The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism
– The report reviews pipeline therapeutics for Secondary Hyperparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Secondary Hyperparathyroidism therapeutics and enlists all their major and minor projects
– The report assesses Secondary Hyperparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism
Purchase a copy of Secondary Hyperparathyroidism-Pipeline Review, H1 2016 visit @ http://www.orbisresearch.com/contact/purchase/142048
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Deltanoid Pharmaceuticals Inc.
Mitsubishi Tanabe Pharma Corporation
OPKO Health, Inc.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Global Markets Direct Report Coverage 6
Secondary Hyperparathyroidism Overview 7
Therapeutics Development 8
Pipeline Products for Secondary Hyperparathyroidism – Overview 8
Secondary Hyperparathyroidism – Therapeutics under Development by Companies 9
Secondary Hyperparathyroidism – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Secondary Hyperparathyroidism – Products under Development by Companies 13
Secondary Hyperparathyroidism – Companies Involved in Therapeutics Development 14
Amgen Inc. 14
Deltanoid Pharmaceuticals Inc. 15
Mitsubishi Tanabe Pharma Corporation 16
Nektar Therapeutics 17
OPKO Health, Inc. 18
Secondary Hyperparathyroidism – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research
Follow us on Twitter: https://twitter.com/orbisresearch
Like us on Facebook: https://www.facebook.com/OrbisResearch